For research use only. Not for therapeutic Use.
Finasteride is a medication used for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB). It is a type II and type III 5α-reductase inhibitor; 5α-reductase, an enzyme, converts testosterone to dihydrotestosterone (DHT).
Catalog Number | A001008 |
CAS Number | 98319-26-7 |
Synonyms | MK-906; 98319-26-7; Proscar; Propecia; Finastid; Prostide |
Molecular Formula | C23H36N2O2 |
Purity | ≥95% |
Target | 5-alpha Reductase |
Solubility | >14.7mg/mL in DMSO |
Storage | -20°C |
InChI | 1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 |
InChIKey | DBEPLOCGEIEOCV-WSBQPABSSA-N |
SMILES | CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C |
Reference | 1: Kaplan SA. Re: Long-Term Consequences of Finasteride vs Placebo in the 2: Meijer M, Thygesen LC, Green A, Emneus M, Brasso K, Iversen P, Pukkala E, 3: Li L, Kang YX, Ji XM, Li YK, Li SC, Zhang XJ, Cui HX, Shi GM. Finasteride 4: Zhao R, Wang X, Jiang C, Shi F, Zhu Y, Yang B, Zhuo J, Jing Y, Luo G, Xia S, 5: Ahmed TA, El-Say KM, Hosny KM, Aljaeid BM. Development of optimized 6: Fouda AM, Bazeed AM. Hematuria and Hematospermia Associated with the Use of 7: Wilson V, Siram K, Rajendran S, Sankar V. Development and evaluation of 8: Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, Kim CY, Park JK. 9: Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model 10: Kaplan SA. Re: Rates of Prostate Surgery and Acute Urinary Retention for |